Evidence of Test Benefitsfishnyc222022-11-01T18:29:55-04:00
Evidence to Support Testing
Two medical professionals discuss the Pros and Cons of universal DPYD pre-screening. Dr. Dan Hertz, PharmD at the University of Michigan presents the benefits of testing while Dr. Suneel D. Kamath, MD at the Cleveland Clinic discusses the challenges with clinical implementation of DPYD testing. Recording date is January 2022.
DPYD variants as predictors of 5-fluorouracil toxicity in adjuvant colon cancer treatment (NCCTG N0147)
“In the largest study to date, (2594 patients with adverse event – AE – data), statistically significant associations were found between DPYD variants (DPYD*2A and D949V) and increased incidence of grade 3 or greater 5FU-AEs in patients treated with adjuvant 5-FU-based combination chemotherapy.”
Patients with DPYD variant associated with deficiency suffered severe toxicity between 50-88% of the time when treated with standard dosing
Dr. Julien Taieb-Hegp’s presentation entitled: “Should DPD Deficiency Be Searched (sic) Before Starting 5FU?” at the World Gastrointestinal Conference of the European Society of Medical Oncologists in 2020.